PLoS ONE (Jan 2015)

Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.

  • Li Wang,
  • Zhenyang Gu,
  • Ruiren Zhai,
  • Shasha Zhao,
  • Lan Luo,
  • Dandan Li,
  • Xiaoli Zhao,
  • Huaping Wei,
  • Zhaoxia Pang,
  • Lili Wang,
  • Daihong Liu,
  • Quanshun Wang,
  • Chunji Gao

DOI
https://doi.org/10.1371/journal.pone.0128763
Journal volume & issue
Vol. 10, no. 5
p. e0128763

Abstract

Read online

Controversy exists regarding whether oral cryotherapy can prevent oral mucositis (OM) in patients with hematological malignancies undergoing hematopoietic stem cell transplantation (HSCT). The aim of the present meta-analysis was to evaluate the efficacy of oral cryotherapy for OM prevention in patients with hematological malignancies undergoing HSCT.PubMed and the Cochrane Library were searched through October 2014. Randomized controlled trials (RCTs) comparing the effect of oral cryotherapy with no treatment or with other interventions for OM in patients undergoing HSCT were included. The primary outcomes were the incidence, severity, and duration of OM. The secondary outcomes included length of analgesic use, total parenteral nutrition (TPN) use, and length of hospital stay.Seven RCTs involving eight articles analyzing 458 patients were included. Oral cryotherapy significantly decreased the incidence of severe OM (RR = 0.52, 95% CI = 0.27 to 0.99) and OM severity (SMD = -2.07, 95% CI = -3.90 to -0.25). In addition, the duration of TPN use and the length of hospitalization were markedly reduced (SMD = -0.56, 95% CI = -0.92 to -0.19; SMD = -0.44, 95% CI = -0.76 to -0.13; respectively). However, the pooled results were uncertain for the duration of OM and analgesic use (SMD = -0.13, 95% CI = -0.41 to 0.15; SMD = -1.15, 95% CI = -2.57 to 0.27; respectively).Oral cryotherapy is a readily applicable and cost-effective prophylaxis for OM in patients undergoing HSCT.